From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已获批准、指定、列入清单、合格、注册、报销或预先授权”的买家自身采购、报销、处方集、规格、采购、网络、目录或计划系统中的选择,从而使得公司未来业务的相当一部分可以在没有每次订单的单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它解锁的大部分量仍在前方,而不是在报告的结果中。 在记录中,管理层讨论了各种业务,如管道、橱柜、油漆等。他们提到了Menards计划,这是一个新的零售计划,正在推出,并预计在第四季度达到8000万美元的年运行率。这似乎是一个新的分销渠道,但这是否意味着公司被列入批准供应商名单或类似系统?管理层说“Menards计划的推出和最初几个月进展顺利,我们按计划在第四季度实现8000万美元的年运行率。”这听起来像是一个新的零售客户,但每个订单仍然需要销售,而不是一个预先存在的系统。此外,他们提到了“Peerless faucet program win at retail”,这是一个零售计划获胜,但同样,这似乎是一个标准客户获胜,而不是一个准入状态。 关于关税,他们讨论了供应链,但没有提到准入状态。 关于Kichler收购,这是一个收购,但那是收购一家公司,而不是被列入系统。 管理层没有明确描述公司被列入任何批准供应商名单、处方集、规格等。他们谈论的是销售增长、市场份额、渠道,但没有提到“已批准”、“指定”、“列入清单”等术语。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.